Smoking Clinical Trial
Official title:
Phase I Study Assessing Safety and Efficacity of NFL101 as Tobacco Therapy(CESTO)
This Phase I study is to investigate the safety of two dose levels of NFL-101 in smokers.
Tobacco addiction is one of the biggest public health threats the world has ever faced,
killing nearly six million people a year. There are more than 1 billion smokers in the world,
up to half will eventually die of a tobacco-related disease. Nicotine replacement treatments
were the first pharmacological treatments approved for use in smoking cessation therapy and
include nicotine gums, transdermal patches, tablets, nasal sprays, and inhalation systems.
More recently, buproprion and varenicline were approved but showed limiting side effects. The
development of safe and efficient alternatives for this indication is now called for.
Tobacco cessation cases were observed concomitantly with the administration of a
desensitization treatment against tobacco allergy. Based on these observations, NFL
Biosciences developed a drug candidate for tobacco cessation. This new drug (NFL 101) was
assessed in preclinical studies. Notably, regulatory genotoxicity (Institut Pasteur de Lille)
and toxicity studies in rats (Ricerca, Wil Research, Lyon) showed no toxicity. The NFL 101
composition and the low doses injected led to propose a mechanism of action based on an
immune response. Immunogenicity studies conducted with the European Georges Pompidou Hospital
(HEGP) on peripheral blood mononuclear cells and rodents have supported such hypotheses.
Therefore, the objective of this Phase I study is to investigate the safety of two dose
levels of NFL-101 in smokers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
| Completed |
NCT02649556 -
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
|
N/A | |
| Completed |
NCT03901066 -
Smoking Dependence and Periodontitis
|
||
| Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
| Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
| Completed |
NCT03305978 -
Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
|
N/A | |
| Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
| Completed |
NCT06105424 -
BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability
|
N/A | |
| Active, not recruiting |
NCT02752022 -
Monitoring the Transition From Smoking to E-cigarettes
|
||
| Completed |
NCT04340830 -
The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants
|
N/A | |
| Completed |
NCT02901171 -
The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation
|
N/A | |
| Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
| Completed |
NCT02912000 -
TEACH: Technology Evaluation to Address Child Health
|
N/A | |
| Completed |
NCT02949648 -
Electronic Cigarette Use and Quitting in Youth
|
N/A | |
| Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
| Completed |
NCT02246114 -
Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women
|
N/A | |
| Completed |
NCT01954407 -
Young Adults' Responses to Anti-smoking Messages
|
N/A | |
| Completed |
NCT01898507 -
Nicotine Metabolism and Low Nicotine Cigarettes
|
N/A | |
| Completed |
NCT02008292 -
Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors
|
N/A |